Barrett-Connor E, Garland C, McPhillips J B, Khaw K T, Wingard D L
Department of Community and Family Medicine, University of California San Diego, La Jolla 92093.
Cancer Res. 1990 Jan 1;50(1):169-73.
Endogenous androgens have been suggested as determinants of risk of prostatic cancer. To examine this possibility, baseline sex hormone levels were measured in 1008 men ages 40-79 years who had been followed for 14 years. There were 31 incident cases of prostatic cancer and 26 identified from death certificates with unknown dates of diagnosis. In this study, total testosterone, estrone, estradiol, and sex hormone-binding globulin were not related to prostate cancer, but plasma androstenedione showed a positive dose-response gradient. Age-adjusted relative risks of prostatic cancer for low (0-2.2 nM), middle (2.3-3.1 nM), and high (3.2+ nM) tertiles of androstenedione were 1.00, 1.34, and 1.98, respectively (P trend less than 0.05). The linear gradient of risk persisted after adjustment for age and body mass index. If confirmed, these data suggest that androstenedione might increase the occurrence of clinically manifest prostatic cancer.
内源性雄激素被认为是前列腺癌风险的决定因素。为了检验这种可能性，对1008名年龄在40 - 79岁且已随访14年的男性测量了基线性激素水平。有31例前列腺癌新发病例，26例从死亡证明中确定，但诊断日期不明。在这项研究中，总睾酮、雌酮、雌二醇和性激素结合球蛋白与前列腺癌无关，但血浆雄烯二酮呈现出正剂量反应梯度。按年龄调整后，雄烯二酮低（0 - 2.2 nM）、中（2.3 - 3.1 nM）、高（3.2 + nM）三分位数组前列腺癌的相对风险分别为1.00、1.34和1.98（P趋势小于0.05）。在调整年龄和体重指数后，风险的线性梯度依然存在。如果得到证实，这些数据表明雄烯二酮可能会增加临床显性前列腺癌的发生率。
